Deciphering the role of gut metabolites in non-alcoholic fatty liver disease

References

• Abrahamse E, Minekus M, van Aken GA, van de Heijning B, Knol J, Bartke N, Oozeer R, van der Beek EM, Ludwig T. 2012. Development of the digestive system—experimental challenges and approaches of infant lipid digestion. Food Dig. 3(1–3):63–77.
   PubMedGoogle Scholar
• Acheson DW, Luccioli S, Gastroenterology RC. 2004. Mucosal immune responses. Best Pract Res Clin Gastroenterol. 18(2):387–404.
   PubMed Web of Science ®Google Scholar
• Agus A, Planchais J, Sokol H. 2018. Gut microbiota regulation of tryptophan metabolism in health and disease. Cell Host Microbe. 23(6):716–724.
   PubMed Web of Science ®Google Scholar
• Ahluwalia B, Magnusson MK, Öhman L. 2017. Mucosal immune system of the gastrointestinal tract: maintaining balance between the good and the bad. Scand J Gastroenterol. 52(11):1185–1193.
   PubMed Web of Science ®Google Scholar
• Aller R, De Luis DA, Izaola O, Conde R, Gonzalez Sagrado M, Primo D, De La Fuente B, Gonzalez J. 2011. Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial. Eur Rev Med Pharmacol Sci. 15(9):1090–1095.
   PubMed Web of Science ®Google Scholar
• Alves-Bezerra M, Cohen D. 2017. Triglyceride metabolism in the liver. Compr Physiol. 8(1):1–8.
   PubMed Web of Science ®Google Scholar
• Aron-Wisnewsky J, Gaborit B, Dutour A, Clement K. 2013. Gut microbiota and non-alcoholic fatty liver disease: new insights. Clin Microbiol Infect. 19(4):338–348.
   PubMed Web of Science ®Google Scholar
• Atreya R, Neurath M. 2010. Factors affecting mucosal homeostasis: a fine balance. Inflammatory bowel disease: translating basic science into clinical practice. New York (NY): John Wiley & Sons; p. 52–63.
   Google Scholar
• Baars A, Oosting A, Knol J, Garssen J, van Bergenhenegouwen J. 2015. The gut microbiota as a therapeutic target in IBD and metabolic disease: a role for the bile acid receptors FXR and TGR5. Microorganisms. 3(4):641–666.
   PubMedGoogle Scholar
• Baker SS, Baker RD, Liu W, Nowak NJ, Zhu L. 2010. Role of alcohol metabolism in non-alcoholic steatohepatitis. PLoS One. 5(3):e9570.
   PubMed Web of Science ®Google Scholar
• Bashiardes S, Shapiro H, Rozin S, Shibolet O, Elinav E. 2016. Non-alcoholic fatty liver and the gut microbiota. Mol Metab. 5(9):782–794.
   PubMed Web of Science ®Google Scholar
• Blaak E, Canfora EE, Theis S, Frost G, Mithieux G, Nauta A, Scott K, Stahl B, van Harsselaar J, van Tol R, et al. 2020. Short chain fatty acids in human gut and metabolic health. Beneficial Microb. 11:411455.
   Web of Science ®Google Scholar
• Bolognini D, Tobin AB, Milligan G, Moss CE. 2016. The pharmacology and function of receptors for short-chain fatty acids. Mol Pharmacol. 89(3):388–398.
   PubMed Web of Science ®Google Scholar
• Bomhof MR, Parnell JA, Ramay HR, Crotty P, Rioux KP, Probert CS, Jayakumar S, Raman M, Reimer RA. 2019. Histological improvement of non-alcoholic steatohepatitis with a prebiotic: a pilot clinical trial. Eur J Nutr. 58(4):1735–1745.
   PubMed Web of Science ®Google Scholar
• Boursier J, Diehl A. 2016. Nonalcoholic fatty liver disease and the gut microbiome. Clin Liver Dis. 20(2):263–275.
   PubMed Web of Science ®Google Scholar
• Boursier J, Mueller O, Barret M, Machado M, Fizanne L, Araujo-Perez F, Guy CD, Seed PC, Rawls JF, David LA, et al. 2016. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology. 63(3):764–775.
   PubMed Web of Science ®Google Scholar
• Brandl K, Schnabl B. 2017. The intestinal microbiota and NASH. Curr Opin Gastroenterol. 33(3):128–133.
   PubMed Web of Science ®Google Scholar
• Chavez-Talavera O, Tailleux A, Lefebvre P, Staels B. 2017. Bile acid control of metabolism and inflammation in obesity, type 2 diabetes, dyslipidemia, and nonalcoholic fatty liver disease. Gastroenterology. 152(7):1679–1694. e3.
   PubMed Web of Science ®Google Scholar
• Chang PV, Hao L, Offermanns S, Medzhitov R. 2014. The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition. Proc Natl Acad Sci USA. 111(6):2247–2252.
   PubMed Web of Science ®Google Scholar
• Chen Z, Lin F, Gao Y, Li Z, Zhang J, Xing Y, Deng Z, Yao Z, Tsun A, Li B, et al. 2011. FOXP3 and RORγt: transcriptional regulation of Treg and Th17. Int Immunopharmacol. 11(5):536–542.
   PubMed Web of Science ®Google Scholar
• Cheroutre H, Lambolez F, Mucida D. 2011. The light and dark sides of intestinal intraepithelial lymphocytes. Nat Rev Immunol. 11(7):445–456.
   PubMed Web of Science ®Google Scholar
• Chriett S, Dąbek A, Wojtala M, Vidal H, Balcerczyk A, Pirola L. 2019. Prominent action of butyrate over β-hydroxybutyrate as histone deacetylase inhibitor, transcriptional modulator and anti-inflammatory molecule. Sci Rep. 9(1):1–14.
   PubMed Web of Science ®Google Scholar
• Cipriani S, Mencarelli A, Chini MG, Distrutti E, Renga B, Bifulco G, Baldelli F, Donini A, Fiorucci S. 2011. The bile acid receptor GPBAR-1 (TGR5) modulates integrity of intestinal barrier and immune response to experimental colitis. PLoS One. 6(10):e25637.
   PubMed Web of Science ®Google Scholar
• Clarke G, Grenham S, Scully P, Fitzgerald P, Moloney RD, Shanahan F, Dinan TG, Cryan JF. 2013. The microbiome-gut-brain axis during early life regulates the hippocampal serotonergic system in a sex-dependent manner. Mol Psychiatry. 18(6):666–673.
   PubMed Web of Science ®Google Scholar
• Collins SM, Surette M, Bercik P. 2012. The interplay between the intestinal microbiota and the brain. Nat Rev Microbiol. 10(11):735–742.
   PubMed Web of Science ®Google Scholar
• Corbin KD, Zeisel S. 2012. Choline metabolism provides novel insights into non-alcoholic fatty liver disease and its progression. Curr Opin Gastroenterol. 28(2):159–165.
   PubMed Web of Science ®Google Scholar
• Craven L, Rahman A, Nair Parvathy S, Beaton M, Silverman J, Qumosani K, Hramiak I, Hegele R, Joy T, Meddings J, et al. 2020. Allogenic fecal microbiota transplantation in patients with nonalcoholic fatty liver disease improves abnormal small intestinal permeability: a randomized control trial. Am J Gastroenterol. 115(7):1055–1065.
   PubMed Web of Science ®Google Scholar
• Cresci GA, Thangaraju M, Mellinger JD, Liu K, Ganapathy V. 2010. Colonic gene expression in conventional and germ-free mice with a focus on the butyrate receptor GPR109A and the butyrate transporter SLC5A8. J Gastrointest Surg. 14(3):449–461.
   PubMed Web of Science ®Google Scholar
• Crotty SJI. 2014. T follicular helper cell differentiation, function, and roles in disease. Immunity. 41(4):529–542.
   PubMed Web of Science ®Google Scholar
• Davani-Davari D, Negahdaripour M, Karimzadeh I, Seifan M, Mohkam M, Masoumi S, Berenjian A, Ghasemi Y. 2019. Prebiotics: definition, types, sources, mechanisms, and clinical applications. Foods. 8(3):92.
   PubMed Web of Science ®Google Scholar
• den Besten G, Bleeker A, Gerding A, van Eunen K, Havinga R, van Dijk TH, Oosterveer MH, Jonker JW, Groen AK, Reijngoud DJ, et al. 2015. Short-chain fatty acids protect against high-fat diet–induced obesity via a PPARγ-dependent switch from lipogenesis to fat oxidation. Diabetes. 64(7):2398–2408.
   PubMed Web of Science ®Google Scholar
• Dewulf EM, Cani PD, Claus SP, Fuentes S, Puylaert PGB, Neyrinck AM, Bindels LB, de Vos WM, Gibson GR, Thissen JP, et al. 2013. Insight into the prebiotic concept: lessons from an exploratory, double blind intervention study with inulin-type fructans in obese women. Gut. 62(8):1112–1121.
   PubMed Web of Science ®Google Scholar
• Donohoe DR, Collins LB, Wali A, Bigler R, Sun W, Bultman SJ. 2012. The Warburg effect dictates the mechanism of butyrate-mediated histone acetylation and cell proliferation. Mol Cell. 48(4):612–626.
   PubMed Web of Science ®Google Scholar
• Dumas ME, Barton RH, Toye A, Cloarec O, Blancher C, Rothwell A, Fearnside J, Tatoud R, Blanc V, Lindon JC, et al. 2006. Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. Proc Natl Acad Sci USA. 103(33):12511–12516.
   PubMed Web of Science ®Google Scholar
• Elshaghabee FMF, Bockelmann W, Meske D, de Vrese M, Walte HG, Schrezenmeir J, Heller KJ. 2016. Ethanol production by selected intestinal microorganisms and lactic acid bacteria growing under different nutritional conditions. Front Microbiol. 7:47.
   PubMed Web of Science ®Google Scholar
• Ferolla SM, Armiliato GNdA, Couto CA, Ferrari TCA. 2015. Probiotics as a complementary therapeutic approach in nonalcoholic fatty liver disease. World J Hepatol. 7(3):559–565.
   PubMedGoogle Scholar
• Fukunishi S, Sujishi T, Takeshita A, Ohama H, Tsuchimoto Y, Asai A, Tsuda Y, Higuchi K. 2014. Lipopolysaccharides accelerate hepatic steatosis in the development of nonalcoholic fatty liver disease in Zucker rats. J Clin Biochem Nutr. 54(1):39–44.
   PubMed Web of Science ®Google Scholar
• Gadaleta RM, van Erpecum KJ, Oldenburg B, Willemsen ECL, Renooij W, Murzilli S, Klomp LWJ, Siersema PD, Schipper MEI, Danese S, et al. 2011. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut. 60(4):463–472.
   PubMed Web of Science ®Google Scholar
• Gao J, Xu K, Liu H, Liu G, Bai M, Peng C, Li T, Yin Y. 2018. Impact of the gut microbiota on intestinal immunity mediated by tryptophan metabolism. Front Cell Infect Microbiol. 8:13.
   PubMed Web of Science ®Google Scholar
• Gómez-Hurtado I, Such J, Sanz Y, Francés R. 2014. Gut microbiota-related complications in cirrhosis. World J Gastroenterol. 20(42):15624–15631.
   PubMed Web of Science ®Google Scholar
• Guo C, Chen WD, Wang YD. 2016. TGR5, not only a metabolic regulator. Front Physiol. 7:646.
   PubMed Web of Science ®Google Scholar
• Guo C, Xie S, Chi Z, Zhang J, Liu Y, Zhang L, Zheng M, Zhang X, Xia D, Ke Y, et al. 2016. Bile Acids Control Inflammation and Metabolic Disorder through Inhibition of NLRP3 Inflammasome. Immunity. 45(4):944.
   PubMed Web of Science ®Google Scholar
• Guo S, Al-Sadi R, Said HM, Ma TY. 2013. Lipopolysaccharide causes an increase in intestinal tight junction permeability in vitro and in vivo by inducing enterocyte membrane expression and localization of TLR-4 and CD14. Am J Pathol. 182(2):375–387.
   PubMed Web of Science ®Google Scholar
• Harrison SA, Rinella ME, Abdelmalek MF, Trotter JF, Paredes AH, Arnold HL, Kugelmas M, Bashir MR, Jaros MJ, Ling L, et al. 2018. NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 391(10126):1174–1185.
   PubMed Web of Science ®Google Scholar
• He F, Li J, Mu Y, Kuruba R, Ma Z, Wilson A, Alber S, Jiang Y, Stevens T, Watkins S, et al. 2006. Downregulation of endothelin-1 by farnesoid X receptor in vascular endothelial cells. Circ Res. 98(2):192–199.
   PubMed Web of Science ®Google Scholar
• Hegade VS, Speight RA, Etherington RE, Jones DEJ. 2016. Novel bile acid therapeutics for the treatment of chronic liver diseases. Therap Adv Gastroenterol. 9(3):376–391.
   PubMed Web of Science ®Google Scholar
• Holt JA, Luo G, Billin AN, Bisi J, McNeill YY, Kozarsky KF, Donahee M, Wang DY, Mansfield TA, Kliewer SA, et al. 2003. Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev. 17(13):1581–1591.
   PubMed Web of Science ®Google Scholar
• Houten SM, Watanabe M, Auwerx J. 2006. Endocrine functions of bile acids. EMBO J. 25(7):1419–1425.
   PubMed Web of Science ®Google Scholar
• Hubbard TD, Murray IA, Perdew GH. 2015. Indole and tryptophan metabolism: endogenous and dietary routes to Ah receptor activation. Drug Metab Dispos. 43(10):1522–1535.
   PubMed Web of Science ®Google Scholar
• Husted AS, Trauelsen M, Rudenko O, Hjorth SA, Schwartz TW. 2017. GPCR-mediated signaling of metabolites. Cell Metab. 25(4):777–796.
   PubMed Web of Science ®Google Scholar
• Inagaki T, Moschetta A, Lee YK, Peng L, Zhao G, Downes M, Yu RT, Shelton JM, Richardson JA, Repa JJ, et al. 2006. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc Natl Acad Sci USA. 103(10):3920–3925.
   PubMed Web of Science ®Google Scholar
• Iwakiri Y, Shah V, Rockey D. 2014. Vascular pathobiology in chronic liver disease and cirrhosis–Current status and future directions. J Hepatol. 61(4):912–924.
   PubMed Web of Science ®Google Scholar
• Jin UH, Cheng Y, Park H, Davidson LA, Callaway ES, Chapkin RS, Jayaraman A, Asante A, Allred A, Weaver EA, et al. 2017. Short chain fatty acids enhance aryl hydrocarbon (Ah) responsiveness in mouse colonocytes and Caco-2 human colon cancer cells. Sci Rep. 7(1):1–12.
   PubMedGoogle Scholar
• Jones SA. 2012. Physiology of FGF15/19. Adv Exp Med Biol. 728:171–182.
   PubMed Web of Science ®Google Scholar
• Katsuma S, Hirasawa A, Tsujimoto G. 2005. Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochem Biophys Res Commun. 329(1):386–390.
   PubMed Web of Science ®Google Scholar
• Kawamata Y, Fujii R, Hosoya M, Harada M, Yoshida H, Miwa M, Fukusumi S, Habata Y, Itoh T, Shintani Y, et al. 2003. AG protein-coupled receptor responsive to bile acids. J Biol Chem. 278(11):9435–9440.
   PubMed Web of Science ®Google Scholar
• Kerry RG, Patra JK, Gouda S, Park Y, Shin HS, Das G. 2018. Benefaction of probiotics for human health: a review. J Food Drug Anal. 26(3):927–939.
   PubMed Web of Science ®Google Scholar
• Kida T, Tsubosaka Y, Hori M, Ozaki H, Murata T. 2013. Bile acid receptor TGR5 agonism induces NO production and reduces monocyte adhesion in vascular endothelial cells. Arterioscler Thromb Vasc Biol. 33(7):1663–1669.
   PubMed Web of Science ®Google Scholar
• Kinoshita M, Suzuki Y, Saito Y. 2002. Butyrate reduces colonic paracellular permeability by enhancing PPARγ activation. Biochem Biophys Res Commun. 293(2):827–831.
   PubMed Web of Science ®Google Scholar
• Kir S, Zhang Y, Gerard RD, Kliewer SA, Mangelsdorf DJ. 2012. Nuclear receptors HNF4α and LRH-1 cooperate in regulating Cyp7a1 in vivo. J Biol Chem. 287(49):41334–41341.
   PubMed Web of Science ®Google Scholar
• Kobyliak N, Abenavoli L, Falalyeyeva T, Mykhalchyshyn G, Boccuto L, Kononenko L, Kyriienko D, Komisarenko I, Dynnyk O. 2018. Beneficial effects of probiotic combination with omega-3 fatty acids in NAFLD: a randomized clinical study. Minerva Med. 109(6):418–428.
   PubMed Web of Science ®Google Scholar
• Koeth RA, Lam-Galvez BR, Kirsop J, Wang Z, Levison BS, Gu X, Copeland MF, Bartlett D, Cody DB, Dai HJ, et al. 2019. l-Carnitine in omnivorous diets induces an atherogenic gut microbial pathway in humans. J Clin Invest. 129(1):373–387.
   PubMed Web of Science ®Google Scholar
• Koh A, De Vadder F, Kovatcheva-Datchary P, Bäckhed F. 2016. From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites. Cell. 165(6):1332–1345.
   PubMed Web of Science ®Google Scholar
• Kondo T, Kishi M, Fushimi T, Kaga T. 2009. Acetic acid upregulates the expression of genes for fatty acid oxidation enzymes in liver to suppress body fat accumulation. J Agric Food Chem. 57(13):5982–5986.
   PubMed Web of Science ®Google Scholar
• Kosiewicz MM, Dryden GW, Chhabra A, Alard P. 2014. Relationship between gut microbiota and development of T cell associated disease. FEBS Lett. 588(22):4195–4206.
   PubMed Web of Science ®Google Scholar
• Krüger R, Merz B, Rist MJ, Ferrario PG, Bub A, Kulling SE, Watzl B. 2017. Associations of current diet with plasma and urine TMAO in the KarMeN study: direct and indirect contributions. Mol Nutr Food Res. 61(11):1700363.
   Web of Science ®Google Scholar
• Kuno T, Hirayama-Kurogi M, Ito S, Ohtsuki S. 2018. Reduction in hepatic secondary bile acids caused by short-term antibiotic-induced dysbiosis decreases mouse serum glucose and triglyceride levels. Sci Rep. 8(1):1253.
   PubMedGoogle Scholar
• Lamas B, Natividad JM, Sokol H. 2018. Aryl hydrocarbon receptor and intestinal immunity. Mucosal Immunol. 11(4):1024–1038.
   PubMed Web of Science ®Google Scholar
• Lamas B, Richard ML, Leducq V, Pham HP, Michel ML, Da Costa G, Bridonneau C, Jegou S, Hoffmann TW, Natividad JM, et al. 2016. CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands. Nat Med. 22(6):598–605.
   PubMed Web of Science ®Google Scholar
• Lambert JE, Parnell JA, Eksteen B, Raman M, Bomhof MR, Rioux KP, Madsen KL, Reimer RA. 2015. Gut microbiota manipulation with prebiotics in patients with non-alcoholic fatty liver disease: a randomized controlled trial protocol. BMC Gastroenterol. 15(1):169.
   PubMedGoogle Scholar
• León-Mimila P, Villamil-Ramírez H, Li XS, Shih DM, Hui ST, Ocampo-Medina E, López-Contreras B, Morán-Ramos S, Olivares-Arevalo M, Grandini-Rosales P, et al. 2021. Trimethylamine N-oxide levels are associated with NASH in obese subjects with type 2 diabetes. Diabetes Metab. 47(2):101183.
   PubMed Web of Science ®Google Scholar
• Leung C, Rivera L, Furness JB, Angus PW. 2016. The role of the gut microbiota in NAFLD. Nat Rev Gastroenterol Hepatol. 13(7):412–425.
   PubMed Web of Science ®Google Scholar
• Li J, Sung CYJ, Lee N, Ni Y, Pihlajamäki J, Panagiotou G, El-Nezami H. 2016. Probiotics modulated gut microbiota suppresses hepatocellular carcinoma growth in mice. Proc Natl Acad Sci USA. 113(9):E1306–E1315.
   PubMed Web of Science ®Google Scholar
• Li J, Wilson A, Kuruba R, Zhang Q, Gao X, He F, Zhang LM, Pitt BR, Xie W, Li S, et al. 2008. FXR-mediated regulation of eNOS expression in vascular endothelial cells. Cardiovasc Res. 77(1):169–177.
   PubMed Web of Science ®Google Scholar
• Li N, Ma WT, Pang M, Fan QL, Hua JL. 2019. The commensal microbiota and viral infection: a comprehensive review. Front Immunol. 10:1551.
   PubMed Web of Science ®Google Scholar
• Li NN, Li W, Feng JX, Zhang WW, Zhang R, Du SH, Liu SY, Xue GH, Yan C, Cui JH, et al. 2021. High alcohol-producing Klebsiella pneumoniae causes fatty liver disease through 2, 3-butanediol fermentation pathway in vivo. Gut Microbes. 13(1):1979883.
   PubMed Web of Science ®Google Scholar
• Lieber C, Research E. 1999. Microsomal ethanol‐oxidizing system (MEOS): the first 30 years (1968‐1998)–a review. Alcohol Clin Exp Res. 23(6):991–1007.
   PubMed Web of Science ®Google Scholar
• Loguercio C, Federico A, Tuccillo C, Terracciano F, D'Auria MV, De Simone C, Del Vecchio Blanco C. 2005. Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J Clin Gastroenterol. 39(6):540–543.
   PubMed Web of Science ®Google Scholar
• Loman BR, Hernández-Saavedra D, An R, Rector RS. 2018. Prebiotic and probiotic treatment of nonalcoholic fatty liver disease: a systematic review and meta-analysis. Nutr Rev. 76(11):822–839.
   PubMed Web of Science ®Google Scholar
• Ma K, Saha PK, Chan L, Moore DD. 2006. Farnesoid X receptor is essential for normal glucose homeostasis. J Clin Invest. 116(4):1102–1109.
   PubMed Web of Science ®Google Scholar
• Ma YY, Li L, Yu CH, Shen Z, Chen LH, Li YM. 2013. Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis. World J Gastroenterol. 19(40):6911–6918.
   PubMed Web of Science ®Google Scholar
• Mabbott NA, Donaldson DS, Ohno H, Williams IR, Mahajan A. 2013. Microfold (M) cells: important immunosurveillance posts in the intestinal epithelium. Mucosal Immunol. 6(4):666–677.
   PubMed Web of Science ®Google Scholar
• MacDonald TT, Monteleone GJS. 2005. Immunity, inflammation, and allergy in the gut. Science. 307(5717):1920–1925.
   PubMed Web of Science ®Google Scholar
• Martin-Gallausiaux C, Marinelli L, Blottière HM, Larraufie P, Lapaque N. 2021. SCFA: mechanisms and functional importance in the gut. Proc Nutr Soc. 80(1):37–49.
   PubMed Web of Science ®Google Scholar
• Maruyama T, Miyamoto Y, Nakamura T, Tamai Y, Okada H, Sugiyama E, Nakamura T, Itadani H, Tanaka K. 2002. Identification of membrane-type receptor for bile acids (M-BAR). Biochem Biophys Res Commun. 298(5):714–719.
   PubMed Web of Science ®Google Scholar
• Medina-Urrutia A, Lopez-Uribe AR, El Hafidi M, González-Salazar MDC, Posadas-Sánchez R, Jorge-Galarza E, Del Valle-Mondragón L, Juárez-Rojas JG. 2020. Chia (Salvia hispanica)-supplemented diet ameliorates non-alcoholic fatty liver disease and its metabolic abnormalities in humans. Lipids Health Dis. 19(1):96.
   PubMed Web of Science ®Google Scholar
• Mizoguchi A, Yano A, Himuro H, Ezaki Y, Sadanaga T, Mizoguchi E. 2018. Clinical importance of IL-22 cascade in IBD. J Gastroenterol. 53(4):465–474.
   PubMed Web of Science ®Google Scholar
• Morgan ET, Dempsey JL, Mimche SM, Lamb TJ, Kulkarni S, Cui JY, Jeong H, Slitt AL. 2018. Physiological regulation of drug metabolism and transport: pregnancy, microbiome, inflammation, infection, and fasting. Drug Metab Dispos. 46(5):503–513.
   PubMed Web of Science ®Google Scholar
• Mowat AM, Agace W. 2014. Regional specialization within the intestinal immune system. Nat Rev Immunol. 14(10):667–685.
   PubMed Web of Science ®Google Scholar
• Mu C, Yang Y, Zhu W. 2016. Gut microbiota: the brain peacekeeper. Front Microbiol. 7:345.
   PubMed Web of Science ®Google Scholar
• Nakao A, Imamura T, Souchelnytskyi S, Kawabata M, Ishisaki A, Oeda E, Tamaki K, Hanai J, Heldin CH, Miyazono K, et al. 1997. TGF-β receptor-mediated signalling through Smad2, Smad3 and Smad4. EMBO J. 16(17):5353–5362.
   PubMed Web of Science ®Google Scholar
• Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, Chalasani N, Dasarathy S, Diehl AM, Hameed B, et al. 2015. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 385(9972):956–965.
   PubMed Web of Science ®Google Scholar
• Oh BR, Hong WK, Heo SY, Joe MH, Seo JW, Kim CH. 2013. The role of aldehyde/alcohol dehydrogenase (AdhE) in ethanol production from glycerol by Klebsiella pneumoniae. J Ind Microbiol Biotechnol. 40(2):227–233.
   PubMed Web of Science ®Google Scholar
• Ohtani N, Kawada N. 2019. Role of the gut–liver axis in liver inflammation, fibrosis, and cancer: a special focus on the gut microbiota relationship. Hepatol Commun. 3(4):456–470.
   PubMed Web of Science ®Google Scholar
• Opazo MC, Ortega-Rocha EM, Coronado-Arrázola I, Bonifaz LC, Boudin H, Neunlist M, Bueno SM, Kalergis AM, Riedel CA. 2018. Intestinal microbiota influences non-intestinal related autoimmune diseases. Front Microbiol. 9:432.
   PubMed Web of Science ®Google Scholar
• Pandey KR, Naik SR, Vakil BV. 2015. Probiotics, prebiotics and synbiotics- a review. J Food Sci Technol. 52(12):7577–7587.
   PubMed Web of Science ®Google Scholar
• Paolella G, Mandato C, Pierri L, Poeta M, Di Stasi M, Vajro P. 2014. Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease. World J Gastroenterol. 20(42):15518–15531.
   PubMed Web of Science ®Google Scholar
• Parks DJ, Blanchard SG, Bledsoe RK, Chandra G, Consler TG, Kliewer SA, Stimmel JB, Willson TM, Zavacki AM, Moore DD, et al. 1999. Bile acids: natural ligands for an orphan nuclear receptor. Science. 284(5418):1365–1368.
   PubMed Web of Science ®Google Scholar
• Peng L, Li ZR, Green RS, Holzman IR, Lin J. 2009. Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers. J Nutr. 139(9):1619–1625.
   PubMed Web of Science ®Google Scholar
• Pernomian L, Duarte-Silva M, de Barros Cardoso CR. 2020. The aryl hydrocarbon receptor (AHR) as a potential target for the control of intestinal inflammation: insights from an immune and bacteria sensor receptor. Clin Rev Allergy Immunol. 59(3):382–390.
   PubMed Web of Science ®Google Scholar
• Peterson LW, Artis D. 2014. Intestinal epithelial cells: regulators of barrier function and immune homeostasis. Nat Rev Immunol. 14(3):141–153.
   PubMed Web of Science ®Google Scholar
• Potthoff MJ, Boney-Montoya J, Choi M, He T, Sunny NE, Satapati S, Suino-Powell K, Xu HE, Gerard RD, Finck BN, et al. 2011. FGF15/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1α pathway. Cell Metab. 13(6):729–738.
   PubMed Web of Science ®Google Scholar
• Pulakazhi Venu VK, Saifeddine M, Mihara K, Tsai Y-C, Nieves K, Alston L, Mani S, McCoy KD, Hollenberg MD, Hirota SA, et al. 2019. The pregnane X receptor and its microbiota-derived ligand indole 3-propionic acid regulate endothelium-dependent vasodilation. Am J Physiol Endocrinol Metab. 317(2):E350–e361.
   PubMed Web of Science ®Google Scholar
• Ralli T, Neupane YR, Saifi Z, Kohli K. 2021. Gut microbiota as an emerging therapeutic avenue for the treatment of nonalcoholic fatty liver disease. Curr Pharm Des. 27(46):4677–4685.
   PubMed Web of Science ®Google Scholar
• Rath S, Heidrich B, Pieper DH, Vital M. 2017. Uncovering the trimethylamine-producing bacteria of the human gut microbiota. Microbiome. 5(1):1–14.
   PubMedGoogle Scholar
• Rath S, Rud T, Karch A, Pieper DH, Vital M. 2018. Pathogenic functions of host microbiota. Microbiome. 6(1):1–13.
   PubMedGoogle Scholar
• Rath S, Rud T, Pieper DH, Vital M. 2019. Potential TMA-producing bacteria are ubiquitously found in mammalia. Front Microbiol. 10:2966.
   PubMed Web of Science ®Google Scholar
• Rosser EC, Piper CJM, Matei DE, Blair PA, Rendeiro AF, Orford M, Alber DG, Krausgruber T, Catalan D, Klein N, et al. 2020. Microbiota-derived metabolites suppress arthritis by amplifying aryl-hydrocarbon receptor activation in regulatory B cells. Cell Metab. 31(4):837–851. e10.
   PubMed Web of Science ®Google Scholar
• Sakakibara S, Yamauchi T, Oshima Y, Tsukamoto Y, Kadowaki T. 2006. Acetic acid activates hepatic AMPK and reduces hyperglycemia in diabetic KK-A (y) mice. Biochem Biophys Res Commun. 344(2):597–604.
   PubMed Web of Science ®Google Scholar
• Sauerbruch T, Hennenberg M, Trebicka J, Beuers U. 2021. Bile acids, liver cirrhosis, and extrahepatic vascular sysfunction. Front Physiol. 12:718783.
   PubMed Web of Science ®Google Scholar
• Scaldaferri F, Pizzoferrato M, Gerardi V, Lopetuso L, Gasbarrini A. 2012. The gut barrier: new acquisitions and therapeutic approaches. J Clin Gastroenterol. 46:s12–S17.
   PubMed Web of Science ®Google Scholar
• Schwenger KJ, Clermont-Dejean N, Allard J. 2019. The role of the gut microbiome in chronic liver disease: the clinical evidence revised. JHEP Rep. 1(3):214–226.
   PubMedGoogle Scholar
• Shavakhi A, Minakari M, Firouzian H, Assali R, Hekmatdoost A, Ferns G. 2013. Effect of a probiotic and metformin on liver aminotransferases in non-alcoholic steatohepatitis: a double blind randomized clinical trial. Int J Prev Med. 4(5):531–537.
   PubMedGoogle Scholar
• Shi LZ, Wang R, Huang G, Vogel P, Neale G, Green DR, Chi H. 2011. HIF1α–dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells. J Exp Med. 208(7):1367–1376.
   PubMed Web of Science ®Google Scholar
• Silva-Sperb AS, Moraes HA, de Moura BC, Alves BC, Bruch-Bertani JP, Azevedo VZ, Dall’Alba V. 2019. Effect of probiotic supplementation in nonalcoholic steatohepatitis patients: PROBILIVER TRIAL protocol. Trials. 20(1):580.
   PubMed Web of Science ®Google Scholar
• Sinha SR, Haileselassie Y, Nguyen LP, Tropini C, Wang M, Becker LS, Sim D, Jarr K, Spear ET, Singh G, et al. 2020. Dysbiosis-induced secondary bile acid deficiency promotes intestinal inflammation. Cell Host Microbe. 27(4):659–670.e5.
   PubMed Web of Science ®Google Scholar
• Stanhope KL, Schwarz JM, Keim NL, Griffen SC, Bremer AA, Graham JL, Hatcher B, Cox CL, Dyachenko A, Zhang W, et al. 2009. Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J Clin Invest. 119(5):1322–1334.
   PubMed Web of Science ®Google Scholar
• Stremmel W, Schmidt KV, Schuhmann V, Kratzer F, Garbade SF, Langhans C-D, Fricker G, Okun JG. 2017. Blood trimethylamine-N-oxide originates from microbiota mediated breakdown of phosphatidylcholine and absorption from small intestine. PLoS One. 12(1):e0170742.
   PubMed Web of Science ®Google Scholar
• Tan J, McKenzie C, Potamitis M, Thorburn AN, Mackay CR, Macia L. 2014. The role of short-chain fatty acids in health and disease. Adv Immunol. 121:91–119.,
   PubMed Web of Science ®Google Scholar
• Tang WHW, Wang Z, Kennedy DJ, Wu Y, Buffa JA, Agatisa-Boyle B, Li XS, Levison BS, Hazen SL. 2015. Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Circ Res. 116(3):448–455.
   PubMed Web of Science ®Google Scholar
• Tarantino G, Finelli C. 2015. Systematic review on intervention with prebiotics/probiotics in patients with obesity-related nonalcoholic fatty liver disease. Future Microbiol. 10(5):889–902.
   PubMed Web of Science ®Google Scholar
• Thangaraju M, Cresci GA, Liu K, Ananth S, Gnanaprakasam JP, Browning DD, Mellinger JD, Smith SB, Digby GJ, Lambert NA, et al. 2009. GPR109A is a G-protein–coupled receptor for the bacterial fermentation product butyrate and functions as a tumor suppressor in colon. Cancer Res. 69(7):2826–2832.
   PubMed Web of Science ®Google Scholar
• US National Library of Medicine (a). 2015. Prebiotic fibre supplementation and gut microbiota in non-alcoholic fatty liver disease. https://ClinicalTrials.gov/show/NCT02568605.
   Google Scholar
• US National Library of Medicine (b). 2015. Prebiotics in patients with non-alcoholic liver disease. https://ClinicalTrials.gov/show/NCT02642172.
   Google Scholar
• US National Library of Medicine (c). 2018. Probiotics in NASH patients - PROBILIVER TRIAL. https://ClinicalTrials.gov/show/NCT03467282.
   Google Scholar
• US National Library of Medicine (d). 2016. Probiotics in the treatment of NAFLD. https://ClinicalTrials.gov/show/NCT02764047.
   Google Scholar
• US National Library of Medicine (e). 2020. Role of probiotics in treatment of pediatric NAFLD patients by assessing with fibroscan. https://ClinicalTrials.gov/show/NCT0467 1186.
   Google Scholar
• US National Library of Medicine (f). 2020. The effect of consecutive fecal microbiota transplantation on non-alcoholic fatty liver disease (NAFLD). https://ClinicalTrials.gov/show/NCT04465032.
   Google Scholar
• US National Library of Medicine (g). 2014. The effect of oral β- glucan supplement on appetite and insulin resistance in non alcoholic fatty liver disease. https://clinicaltrials.gov/ct2/show/NCT02178839.
   Google Scholar
• US National Library of Medicine (h). 2019. The effect of probiotics on the clinical outcomes and gut microenvironment in patients with fatty liver. https://ClinicalTrials.gov/show/NCT04074889.
   Google Scholar
• US National Library of Medicine (i). 2022. To evaluate the beneficial effect of probiotics on NAFLD patients and the role of gut microbiota modulation. https://ClinicalTrials.gov/show/NCT05402449.
   Google Scholar
• US National Library of Medicine (j). 2015. Transplantation of microbes for treatment of metabolic syndrome & NAFLD. https://ClinicalTrials.gov/show/NCT02496390.
   Google Scholar
• US National Library of Medicine (k). 2009. Treatment of nonalcoholic fatty liver disease with probiotics and prebiotics. https://ClinicalTrials.gov/show/NCT00870012.
   Google Scholar
• US National Library of Medicine (l). 2019. Chia supplementation and non alcoholic fatty liver disease. https://clinicaltrials.gov/ct2/show/NCT03942822.
   Google Scholar
• US National Library of Medicine (m). 2005. Effect of omega-3 PUFA supplementation in NAFLD patients. https://clinicaltrials.gov/ct2/show/NCT00230113.
   Google Scholar
• US National Library of Medicine (n). 2008. Effect of probiotic co-administration with omega-3 fatty acids on NAFLD. https://ClinicalTrials.gov/show/NCT03528707.
   Google Scholar
• US National Library of Medicine (o). 2022. Effect of probiotics in non-alcoholic fatty liver disease and steatohepatitis. https://ClinicalTrials.gov/show/NCT04175392.
   Google Scholar
• US National Library of Medicine (p). 2017. Effects of dietary fructose on gut microbiota and fecal metabolites in obese men and postmenopausal women: a pilot study. https://clinicaltrials.gov/ct2/show/NCT03339245.
   Google Scholar
• US National Library of Medicine (q). 2022. Effects of fecal microbiota transplantation on weight in obese patients with non-alcoholic fatty liver disease. https://ClinicalTrials.gov/show/NCT04594954.
   Google Scholar
• US National Library of Medicine (r). 2018. Effects of probiotic on inflammation and microbiota in patients with NASH. https://ClinicalTrials.gov/show/NCT03511365.
   Google Scholar
• US National Library of Medicine (s). 2020. Effects of probiotics (P. Pentosaceus, L. Lactis or L. Helveticus) in NASH. https://ClinicalTrials.gov/show/NCT04555434.
   Google Scholar
• US National Library of Medicine (t). 2021. Efficacy and safety of a probiotic composition as adjunct in MAFL management. https://ClinicalTrials.gov/show/NCT04823676.
   Google Scholar
• US National Library of Medicine (u). 2018. Efficacy of silymarin in patients with non-alcoholic fatty liver disease - the SILIVER trial. https://clinicaltrials.gov/ct2/show/NCT03749070.
   Google Scholar
• US National Library of Medicine (v). 2016. Fecal microbiota therapy versus standard therapy in NASH related cirrhosis. https://ClinicalTrials.gov/show/NCT02721264.
   Google Scholar
• US National Library of Medicine (w). 2015. Fecal microbiota transplantation (FMT) in nonalcoholic steatohepatitis(NASH). A pilot study. https://ClinicalTrials.gov/show/NCT02469272.
   Google Scholar
• US National Library of Medicine (x). 2019. Fecal microbiota transplantation for the treatment of non-alcoholic steatohepatitis. https://ClinicalTrials.gov/show/NCT03803540.
   Google Scholar
• US National Library of Medicine (y). 2017. Histological improvement of NASH with prebiotic. https://ClinicalTrials.gov/show/NCT03184376.
   Google Scholar
• Vavassori P, Mencarelli A, Renga B, Distrutti E, Fiorucci S. 2009. The bile acid receptor FXR is a modulator of intestinal innate immunity. J Immunol. 183(10):6251–6261.
   PubMed Web of Science ®Google Scholar
• Venkatesh M, Mukherjee S, Wang H, Li H, Sun K, Benechet AP, Qiu Z, Maher L, Redinbo MR, Phillips RS, et al. 2014. Symbiotic bacterial metabolites regulate gastrointestinal barrier function via the xenobiotic sensor PXR and Toll-like receptor 4. Immunity. 41(2):296–310.
   PubMed Web of Science ®Google Scholar
• Vipperla K, O’Keefe SJ. 2012. The microbiota and its metabolites in colonic mucosal health and cancer risk. Nutr Clin Pract. 27(5):624–635.
   PubMed Web of Science ®Google Scholar
• Vrieze A, Van Nood E, Holleman F, Salojärvi J, Kootte RS, Bartelsman JFWM, Dallinga-Thie GM, Ackermans MT, Serlie MJ, Oozeer R, et al. 2012. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology. 143(4):913–916.e7.
   PubMed Web of Science ®Google Scholar
• Wahlstram A, Sayin SI, Marschall HU, Bäckhed F. 2016. Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. Cell Metab. 24(1):41–50.
   PubMed Web of Science ®Google Scholar
• Wang JW, Kuo CH, Kuo FC, Wang YK, Hsu WH, Yu FJ, Hu HM, Hsu PI, Wang JY, Wu DC, et al. 2019. Fecal microbiota transplantation: review and update. J Formos Med Assoc. 118(1):s23–s31.
   PubMedGoogle Scholar
• Wang Z, Bergeron N, Levison BS, Li XS, Chiu S, Jia X, Koeth RA, Li L, Wu Y, Tang WHW, et al. 2019. Impact of chronic dietary red meat, white meat, or non-meat protein on trimethylamine N-oxide metabolism and renal excretion in healthy men and women. Eur Heart J. 40(7):583–594.
   PubMed Web of Science ®Google Scholar
• Watanabe M, Houten SM, Wang L, Moschetta A, Mangelsdorf DJ, Heyman RA, Moore DD, Auwerx J. 2004. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest. 113(10):1408–1418.
   PubMed Web of Science ®Google Scholar
• Willard-Mack C. 2006. Normal structure, function, and histology of lymph nodes. Toxicol Pathol. 34(5):409–424.
   PubMed Web of Science ®Google Scholar
• Williams BB, Van Benschoten AH, Cimermancic P, Donia MS, Zimmermann M, Taketani M, Ishihara A, Kashyap PC, Fraser JS, Fischbach MA, et al. 2014. Discovery and characterization of gut microbiota decarboxylases that can produce the neurotransmitter tryptamine. Cell Host Microbe. 16(4):495–503.
   PubMed Web of Science ®Google Scholar
• Wlodarska M, Luo C, Kolde R, d‘Hennezel E, Annand JW, Heim CE, Krastel P, Schmitt EK, Omar AS, Creasey EA, et al. 2017. Indoleacrylic acid produced by commensal peptostreptococcus species suppresses inflammation. Cell Host Microbe. 22(1):25–37.e6.
   PubMed Web of Science ®Google Scholar
• Wong VWS, Won GLH, Chim AML, Chu WCW, Yeung DKW, Li KCT, Chan HLY. 2013. Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study. Ann Hepatol. 12(2):256–262.
   PubMed Web of Science ®Google Scholar
• Wu HJ, Wu E. 2012. The role of gut microbiota in immune homeostasis and autoimmunity. Gut Microbes. 3(1):4–14.
   PubMed Web of Science ®Google Scholar
• Yano JM, Yu K, Donaldson GP, Shastri GG, Ann P, Ma L, Nagler CR, Ismagilov RF, Mazmanian SK, Hsiao EY, et al. 2015. Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell. 161(2):264–276.
   PubMed Web of Science ®Google Scholar
• Yao Y, Cai X, Fei W, Ye Y, Zhao M, Zheng C. 2022. The role of short-chain fatty acids in immunity, inflammation and metabolism. Crit Rev Food Sci Nutr. 62(1):1–12.
   PubMed Web of Science ®Google Scholar
• Yuan J, Chen C, Cui J, Lu J, Yan C, Wei X, Zhao X, Li N, Li S, Xue G, et al. 2019. Fatty liver disease caused by high-alcohol-producing Klebsiella pneumoniae. Cell Metab. 30(4):675–688. e7.
   PubMed Web of Science ®Google Scholar
• Zapolska-Downar D, Siennicka A, Kaczmarczyk M, Kołodziej B, Naruszewicz M. 2004. Butyrate inhibits cytokine-induced VCAM-1 and ICAM-1 expression in cultured endothelial cells: the role of NF-κB and J Nutr Biochem. 15(4):220–228.
   PubMed Web of Science ®Google Scholar
• Zelante T, Iannitti RG, Cunha C, De Luca A, Giovannini G, Pieraccini G, Zecchi R, D'Angelo C, Massi-Benedetti C, Fallarino F, et al. 2013. Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. Immunity. 39(2):372–385.
   PubMed Web of Science ®Google Scholar
• Zhang H, Caudle Y, Wheeler C, Zhou Y, Stuart C, Yao B, Yin D. 2018. TGF-β1/Smad2/3/Foxp3 signaling is required for chronic stress-induced immune suppression. J Neuroimmunol. 314:30–41.
   PubMed Web of Science ®Google Scholar